SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Link Pharma Chem - Quaterly Results

07 Feb 2025 Evaluate
The sales for the December 2024 quarter moved down -32.71% to Rs. 53.42 millions as compared to Rs. 79.39 millions during the year ago period.The Net Loss for the quarter ended December 2024 is Rs. -6.66 millions as compared to Net Profit of Rs. 2.21 millions of corresponding quarter ended December 2023Operating profit Margin for the quarter ended December 2024 slipped to -4.50% as compared to 6.49% of corresponding quarter ended December 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 53.42 79.39 -32.71 189.86 218.65 -13.17 298.98 387.58 -22.86
Other Income -5.62 3.70 -251.89 0.69 6.51 -89.40 6.40 -1.47 -535.37
PBIDT -4.50 6.49 -169.34 4.22 -9.19 -145.92 -0.09 25.69 -100.35
Interest 2.05 2.31 -11.26 6.34 6.78 -6.49 8.72 7.61 14.59
PBDT -6.55 4.18 -256.70 -2.12 -15.97 -86.73 -8.81 18.08 -148.73
Depreciation 2.35 2.66 -11.65 7.06 7.85 -10.06 10.34 9.23 12.03
PBT -8.90 1.52 -685.53 -9.18 -23.82 -61.46 -19.15 8.85 -316.38
TAX -2.24 -0.69 224.64 -2.43 -7.58 -67.94 -5.53 2.32 -338.36
Deferred Tax -2.24 -0.69 224.64 -2.43 -7.64 -68.19 -5.59 -1.83 205.46
PAT -6.66 2.21 -401.36 -6.75 -16.24 -58.44 -13.62 6.53 -308.58
Equity 44.41 44.41 0.00 44.41 44.41 0.00 44.41 44.41 0.00
PBIDTM(%) -8.42 8.17 -203.05 2.22 -4.20 -152.88 -0.03 6.63 -100.45

Link Pharma Chem Share Price

28.59 -0.09 (-0.31%)
13-Apr-2026 16:01 View Price Chart
Peers
Company Name CMP
BASF India 3580.10
Tata Chemicals 718.85
SRF 2427.55
Pidilite Inds. 1330.00
Deepak Nitrite 1475.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×